Search Results for: Gestione del trattamento del Morbo di Parkinson

Introduction
Cognitive impairment is reported in a variety of clinical conditions including Alzheimer’s disease, Parkinson’s and ‘long-COVID’. Interestingly, many of these clinical conditions are also associated with microbial dysbiosis. This comanifestation of cognitive and microbiome findings in seemingly unrelated maladies suggests that they could share a common mechanism and potentially presents a treatment target. Although a rapidly growing body of literature has documented this comorbid presentation within specific conditions, an overview highlighting potential parallels across healthy and clinical populations is lacking. The objective of this umbrella review, therefore, is to summarise and synthesise the findings of these systematic reviews.

Methods and analysis
On 2 April 2023, we searched MEDLINE (Pubmed), Embase (Ovid), the Web of Science (Core Collection), the Cochrane Library of Systematic Reviews and Epistemonikos as well as grey literature sources, for systematic reviews on clinical conditions and interventions where cognitive and microbiome outcomes were coreported. An updated search will be conducted before completion of the project if the search-to-publication date is >1 year old. Screening, data abstraction and quality assessment (AMSTAR 2, A MeaSurement Tool to Assess systematic Reviews) will be conducted independently and in duplicate, with disagreements resolved by consensus. Evidence certainty statements for each review’s conclusions (eg, Grading of Recommendations Assessment, Development and Evaluation (GRADE)) will be extracted or constructed de novo. A narrative synthesis will be conducted and delineated by the review question. Primary study overlap will be visualised using a citation matrix as well as calculated using the corrected covered area method.

Ethics and dissemination
No participant-identifying information will be used in this review. No ethics approval was required due to our study methodology. Our findings will be presented at national and international conferences and disseminated via social media and press releases. We will recruit at least one person living with cognitive impairment to collaborate on writing the plain language summary for the review.

PROSPERO registration number
CRD42023412903

Recenti pubblicazioni hanno riaperto domande sulle modalità di cura indicando percorsi da affiancare al trattamento farmacologico

Introduction
Neuropsychiatric symptoms (NPS) are common non-motor symptoms among patients with Parkinson’s disease (PD) and significantly impact their overall quality of life detrimentally. Several studies have reported the clinical effect of acupuncture therapy in treating NPS in PD. Therefore, the objective of this systematic review is to evaluate the potential inclusion of acupuncture therapy as an integral component of complementary treatment for PD with NPS.

Methods and analysis
From their inception until 1 December 2023, we will search eight databases, including PubMed, Cochrane Library, Embase, Web of Science, China National Knowledge Infrastructure, China Science Periodical Database, Chinese Citation Database and China Biology Medicine disc for randomised controlled trials examining the effectiveness of acupuncture for PD with NPS. Literature screening and data extraction will be carried out independently by the authors. RevMan V.5.3 software will be used for meta-analysis, while the Cochrane risk-of-bias tool will assess the potential for bias.

Ethics and dissemination
This systematic review protocol does not require ethical approval because it does not include private information or data of participants. This article will be published in a peer-reviewed journal.

PROSPERO registration number
CRD42022324494

La Commissione europea ha concesso l’autorizzazione per l’insulina settimanale, Awiqli di Novo Nordisk, la prima al mondo indicata per il trattamento del diabete negli adulti. «Il farmaco – spiega una nota – è progettato per coprire il fabbisogno di insulina basale per un’intera settimana con una singola iniezione sottocutanea ed è stato approvato per gli adulti con diabete mellito»

We read with interest the recent article by Zhang et al that reported a higher risk of developing dementia in patients with inflammatory bowel disease (IBD), with the largest increase in Alzheimer’s disease (AD).1 These findings align with a growing body of evidence which links gut inflammation or leaky gut with neurodegeneration. Lee et al discussed the known shared pathophysiological links between IBD and Parkinson’s disease (PD), underscoring the importance of genetic overlap, microbiota gut-brain axis, autoimmunity, mitochondrial function and autophagy.2 We would like to highlight another less-explored biological connection: microRNAs (miRNAs). miRNAs are small non-coding RNAs, which regulate gene expression at the post-transcriptional level by silencing targeting mRNA(s). Intriguingly, miRNAs have been implicated in the pathogenesis of both IBD and neurodegenerative diseases (NDDs). miRNAs have emerged as important regulators of gut and blood–brain barrier (BBB) integrity.3 4 Complementing these findings,…